CASIFOTCPharmaceutical PreparationsFiscal year ends December 31

CASI Pharmaceuticals, Inc.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on May 15, 2026

$0.10+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

CASI Pharmaceuticals, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	Q4 2025 2025-12-31	Q4 2024 2024-12-31	Q4 2023 2023-12-31	Q4 2022 2022-12-31	Q4 2021 2021-12-31	Q4 2020 2020-12-31	Q4 2019 2019-12-31
Cash & Equivalents	5.63	13	17	47	39	–	–
Short-Term Investments	–	–	12	1.46	9.87	–	–
Cash & Short-Term Investments	5.63	13	29	49	49	–	–
Receivables	4.09	15	9.55	13	9.80	–	–
Inventory	1.60	5.25	16	6.14	1.91	–	–
Prepaid Expenses & Other	2.14	2.89	2.56	2.98	1.69	–	–
Total Current Assets	13	40	59	73	62	–	–
Property, Plant & Equipment	6.97	7.87	9.24	12	13	–	–
Gross Property, Plant & Equipment	14	14	14	14	15	–	–
Accumulated Depreciation	-7.09	-5.71	-4.65	-2.30	-1.82	–	–
Machinery & Equipment	6.20	5.94	6.00	0.62	–	–	–
Construction in Progress	–	–	0.02	5.73	12	–	–
Long-Term Investments	1.72	1.91	1.69	4.40	40	–	–
Operating Lease Right-of-Use Assets	2.55	3.49	2.39	1.40	9.11	–	–
Intangible Assets	0.22	0.24	1.84	1.06	12	13	14
Other Long-Term Assets	0.74	0.59	0.77	1.06	2.18	–	–
Total Assets	26	54	75	96	138	–	–
Accounts Payable	1.07	2.72	4.44	3.29	2.22	–	–
Current Portion of Long-Term Debt	19	18	–	–	–	–	–
Current Debt	19	18	–	–	–	–	–
Current Portion of Leases	1.61	1.22	0.73	0.87	1.06	–	–
Current Income Taxes Payable	–	–	–	1.90	–	–	–
Other Current Liabilities	2.23	1.33	1.12	0.65	0.52	–	–
Total Current Liabilities	50	36	17	17	13	–	–
Long-Term Debt	–	–	19	–	–	–	–
Long-Term Leases	1.44	2.54	1.62	0.48	1.11	–	–
Operating Lease Liabilities	3.05	3.76	2.34	1.34	2.17	–	–
Other Long-Term Liabilities	13	15	15	12	14	–	–
Total Liabilities	63	52	51	29	30	–	–
Total Debt	19	18	19	–	–	–	–
Common Stock	0.00	0.00	0.00	0.00	0.00	–	–
Additional Paid-In Capital	722	713	696	692	696	–	–
Retained Earnings	-748	-700	-661	-637	-606	–	–
Treasury Stock	-9.60	-9.60	-9.60	-9.33	-8.03	–	–
Comprehensive Income & Other	-1.79	-1.77	-1.20	-0.70	1.95	–	–
Shareholders' Equity	-37	1.85	24	45	85	82	73
Total Equity	-37	1.85	24	45	85	82	73
Total Liabilities & Equity	26	54	75	96	138	–	–
Shares Outstanding(shares)	21	15	13	13	14	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin: 48.6%
Operating margin: -217.3%
Net margin: -232.0%
Return on equity, FY2025: 271.3%

Financial strength

Current ratio: 0.27
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 11.3%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –